Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the Treatment of CMV Viremia or Disease

NCT03010332 · clinicaltrials.gov ↗

NO_LONGER_AVAILABLE

Status

INDUSTRY

Sponsor class

Conditions

CMV Viremia
CMV Disease

Interventions

BIOLOGICAL: Cytomegalovirus-specific Cytotoxic T Lymphocytes (CMV-CTLs)

Sponsor

Atara Biotherapeutics